Drug Profile
BGE 117
Alternative Names: BGE-117; TS-143Latest Information Update: 23 Jun 2022
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Developer BioAge Labs; Taisho Pharmaceutical
- Class Small molecules
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anaemia
- Discontinued Renal failure
Most Recent Events
- 05 May 2022 BioAge Labs withdraws a phase II clinical trial for Anaemia (In the elderly) in Australia prior to enrolment, as of May 2022 (PO) (NCT05152641)
- 01 May 2022 Phase-II clinical trials in Anaemia (In the elderly) in Australia (PO) (BioAge Labs pipeline, May 2022)
- 01 Apr 2022 BioAge Labs withdraws a phase II clinical trial in Anaemia (In the elderly) in Australia prior to enrolment, in April 2022 (PO) (NCT04815603)